

[For Immediate Release]

1 September 2021



Uni-Bio Science Group and Alephoson Biopharmaceuticals Announce Partnership to Co-Develop Next-generation Best-in-class Compounds

[1 September 2021 – Hong Kong] A fully integrated biopharmaceutical company – Uni-Bio Science Group Limited (the “Company”, together with its subsidiaries, the “Group”; Stock code: 00690.HK) is pleased to announce that the company has formed a strategic alliance with Alephoson Biopharmaceuticals Ltd. (“Alephoson”) to explore the use of Cell Penetration Protein Alternation Technology (CePPA) with the Group’s next generation, best-in-class compounds for patients with retinal diseases and other potential therapeutic areas. The partnership will involve a close collaboration between the two companies.

Alephoson is a technology-based biopharmaceutical company focusing on innovative CePPA delivery system, which facilitates cellular intake and uptake of molecules like nanosize particles, commonly through endocytosis. The "cargo" is associated with the peptides either through chemical linkage via covalent bonds or through non-covalent interactions. In recent years, a great number of studies reported the potential of Cell penetrating peptides (CPPs) as carriers for the treatment of various diseases. Apart from a good efficacy due to a rapid and potent delivery, a crucial advantage of CPP-based therapies is the peptides low toxicity and efficiency compared to most other drug carriers.

“We are excited to collaborate with UniBio to explore opportunities in the ophthalmology and dermatology . CePPA technology is a patented and disruptive drug delivery platform aiming to provide a non-invasive treatment alternatives to present medical cares and to overcome certain drug formulation limitations. We are excited that this partnership will further advance patient care, as well as taking this technology and its application to a new level .” said Dr. Benjamin Lee, CEO and Founder of Alephoson Biopharmaceuticals Ltd.

“Forming partnerships and alliances helps in risk mitigation for companies in the initial R&D stages. The target

聯康生物科技集團 Uni-Bio Science Group Limited

Unit 502, 5/F, No. 20 Science Park East Avenue, Hong Kong Science Park, Shatin, New Territories, Hong Kong

香港新界沙田香港科學園科技大道東 20 號 5 樓 502 室

Tel: +852 3102 3232 Email: ir@uni-bioscience.com Website: www.uni-bioscience.com

奧朗生物醫藥 Alephoson Biopharmaceuticals Limited

Unit 325, 3/F, Building 16W, No. 16 Science Park West Avenue, Hong Kong Science Park, Pak Shek Kok, Hong Kong

香港新界沙田香港科學園科技大道西 16 號 3 樓 325 室

Tel: +852 6737 2711 Email: blee@alephoson.com

market for us provides a plethora of opportunities to partner with different kinds of organizations ranging from the CROs to private companies. Involving Alephoson as our strategic alliance not only aligns with our long-term development plan of expanding our pipeline of next-generation drugs, but also diversifies formulation choices of our marketed products. We believe the partnership, along with our solid experience in commercialization, will bring more innovative products to the market.” said Mr. Kingsley Leung, Chairman of Uni-Bio Science Group.

-End-

聯康生物科技集團 Uni-Bio Science Group Limited

Unit 502, 5/F, No. 20 Science Park East Avenue, Hong Kong Science Park, Shatin, New Territories, Hong Kong

香港新界沙田香港科學園科技大道東 20 號 5 樓 502 室

Tel: +852 3102 3232 Email: ir@uni-bioscience.com Website: www.uni-bioscience.com

奧朗生物醫藥 Alephoson Biopharmaceuticals Limited

Unit 325, 3/F, Building 16W, No. 16 Science Park West Avenue, Hong Kong Science Park, Pak Shek Kok, Hong Kong

香港新界沙田香港科學園科技大道西 16 號 3 樓 325 室

Tel: +852 6737 2711 Email: blee@alephoson.com

About Uni-Bio Science Group

Uni-Bio Science Group Limited is principally engaged in the research and development, manufacture and distribution of biopharmaceutical products. The research and development center is fully equipped with a complete system for the development of genetically-engineered products with a pilot plant test base which is in line with NMPA requirements. The Group has two GMP manufacturing bases in Beijing and Shenzhen. The Group also has a highly efficient commercialization platform and marketing network. The Group focuses on the development of novel treatments and innovative drugs addressing the therapeutic areas of endocrine such as diabetes and osteoporosis, ophthalmology and dermatology. Please visit the official website of Uni-Bio Science Group for more information: www.uni-bioscience.com/

About Alephoson Biopharmaceuticals Ltd.

Alephoson Biopharmaceuticals Limited (AB) is a private, technology-based company focusing on research and development of innovative drug delivery technologies to fulfil unmet medical needs. By utilizing the destructive, and proprietary next generation Cell Penetration Protein Alternation Technology (CePPA), we are working to overcome the limitations of current treatments for serious ophthalmic diseases by developing a topical eye drop alternative to intravitreal (back-of-the eye) injection therapies. At AB, we understand the critical role vision plays in a patient's quality of life, and we know the frustration that ophthalmologists face when they are unable to treat their patients successfully, and for patients and families for whom the burden of chronic treatment can be overwhelming. We are determined to develop new ocular therapies that help patients see their very best throughout their lives. Our management team and board of directors bring extensive experience discovering, evaluating, developing, and commercializing drugs. These novel therapies may include improvements to existing medicines or entirely new molecules. Please visit Alephoson Biopharmaceuticals Ltd official website www.alephoson.com for more information.

For further information, please contact: ir@uni-bioscience.com

聯康生物科技集團 Uni-Bio Science Group Limited

Unit 502, 5/F, No. 20 Science Park East Avenue, Hong Kong Science Park, Shatin, New Territories, Hong Kong

香港新界沙田香港科學園科技大道東 20 號 5 樓 502 室

Tel: +852 3102 3232 Email: ir@uni-bioscience.com Website: www.uni-bioscience.com

奧朗生物醫藥 Alephoson Biopharmaceuticals Limited

Unit 325, 3/F, Building 16W, No. 16 Science Park West Avenue, Hong Kong Science Park, Pak Shek Kok, Hong Kong

香港新界沙田香港科學園科技大道西 16 號 3 樓 325 室

Tel: +852 6737 2711 Email: blee@alephoson.com